Two-year outcome of a randomized trial comparing second-generation drug-eluting stents using biodegradable or durable polymer

JAMA

Volumn 311, Issue 20, 2014, Pages 2125-2127

  Natsuaki, Masahiro ^a   Kozuma, Ken ^b   Morimoto, Takeshi ^c   Shiomi, Hiroki ^d   Kimura, Takeshi ^d  

^a SAISEIKAI FUKUOKA GENERAL HOSPITAL   (Japan)

^b TEIKYO UNIVERSITY HOSPITAL   (Japan)

^c HYOGO COLLEGE OF MEDICINE   (Japan)

^d KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBOCYTIC AGENT; EVEROLIMUS; POLYMER; UMIROLIMUS;

BLEEDING; CORONARY ARTERY BYPASS GRAFT; DEATH; DEVICE SAFETY; DRUG ELUTING STENT; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; LETTER; PRIORITY JOURNAL; STENT THROMBOSIS; THERAPY EFFECT; TREATMENT OUTCOME;

BIODEGRADABLE PLASTICS; DRUG-ELUTING STENTS; HUMANS; MYOCARDIAL INFARCTION; POLYMERS; RISK; SIROLIMUS; SURVIVAL ANALYSIS; THROMBOSIS; TREATMENT OUTCOME;

EID: 84901631438     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2014.3584     Document Type: Letter

References (4)

1. Bangalore S, Toklu B, Amoroso N, et al. Baremetal stents, durable polymer drug eluting stents, and biodegradable polymer drug eluting stents for coronary artery disease: mixed treatment comparison meta-analysis. BMJ. 2013;347:f6625.
2. Navarese EP, Tandjung K, Claessen B, et al. Safety and efficacy outcomes of first and second generation durable polymer drug eluting stents and biodegradable polymer biolimus eluting stents in clinical practice: comprehensive networkmeta-analysis. BMJ. 2013;347:f6530.
3. Kang SH, Park KW, Kang DY, et al. Biodegradable-polymer drug-eluting stents vs baremetal stents vs durable-polymer drug-eluting stents: a systematic review and Bayesian approach networkmeta-analysis [published online January 23, 2014]. Eur Heart J. doi:10.1093/eurheartj/eht570.
4. Natsuaki M, Kozuma K, Morimoto T, et al; NEXT Investigators. Biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent: a randomized, controlled, noninferiority trial. J Am Coll Cardiol. 2013;62(3):181-190.